Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00810888 · ClinicalTrials.gov registry record · Phase 2

The Spot Sign for Predicting and Treating ICH Growth Study

A Phase 2 study of Intracerebral Hemorrhage, sponsored by University of Cincinnati.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
10
Study locations

NCT00810888: Completed Phase 2 study of Intracerebral Hemorrhage, sponsored by University of Cincinnati.

NCT00810888 is a Phase 2 study of Intracerebral Hemorrhage that has completed, run by University of Cincinnati. The registered enrollment target is 92 participants, below the 1,103-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (92% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00810888, a Phase 2 study of Intracerebral Hemorrhage, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.

Primary Outcome

Thromboembolic complications are defined as development of (1) acute myocardial ischemia; or (2) acute cerebral ischemia; or (3) acute pulmonary embolism

Conditions Studied

Intracerebral Hemorrhage

Interventions

  • DRUG placebo
  • DRUG recombinant activated factor VII

Study Locations (10)

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix

California

  • University of California, San Diego - San Diego

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University - St Louis

Ohio

  • University of Cincinnati-Clinical Coordinating Center - Cincinnati

South Carolina

  • Medical University of South Carolina - Charleston

Alberta

  • University of Calgary - Calgary

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2010-11
Est. Completion 2016-04
Phase Phase 2
University of Cincinnati

245 total trials

What the finished NCT00810888 record still lists

NCT00810888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,103-participant average among 31 other Intracerebral Hemorrhage trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00810888 lists 10 locations in 9 states (Pennsylvania, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT00810888 about?

NCT00810888 is a clinical study titled "The Spot Sign for Predicting and Treating ICH Growth Study". The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recom...

What is the current status of trial NCT00810888?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2010-11. Estimated completion is 2016-04.

What conditions does trial NCT00810888 study?

This clinical trial studies the following conditions: Intracerebral Hemorrhage.

What interventions are being tested in trial NCT00810888?

The interventions under investigation include: placebo (DRUG), recombinant activated factor VII (DRUG).

Who is sponsoring clinical trial NCT00810888?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00810888 being conducted?

This trial has 10 study locations across Arizona, California, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Intracerebral Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00810888's enrollment target sits among peer trials

92 22nd of 31 higher than 10 of 31 other Intracerebral Hemorrhage trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Intracerebral Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00810888, the US trial registry maintained by the National Library of Medicine. NCT00810888 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.